Deutsche Bank Takes EUR257 Million Hit On Actavis-Watson Deal
April 25 2012 - 05:25PM
Dow Jones News
Deutsche Bank AG (DB, DBK.XE) said Wednesday it will book a
EUR257 million impairment charge in the first quarter from exiting
its exposure to generic drug maker Actavis, which will be sold to
U.S. competitor Watson Pharmaceuticals Inc (WPI).
"The transaction is expected to close in the fourth quarter of
2012," and will lead to a Core Tier 1 capital accretion of
approximately EUR290 million, Deutsche Bank said.
Actavis in a separate statement said Wednesday that it will be
bought by U.S. peer Watson in a EUR4.5 billion ($5.92 billion)
deal.
Actavis was taken private in 2007 by Icelandic billionaire Thor
Bjorgolfsson's private-equity firm Novator in a roughly $5 billion
deal. The chunk of the leverage buyout loan came from German lender
Deutsche Bank. Actavis then went on an acquisition spree, snapping
up generic-drug companies all over the world, building a big debt
load in the process.
Deutsche Bank, which will release its first-quarter figures
Thursday, reportedly took charge at Actavis when a big chunk of Mr.
Bjorgolfsson's wealth was wiped out in late 2008 through the
collapse of Icelandic bank Landsbanki Islands hf, making a
restructuring of Actavis debt necessary.
-By Eyk Henning, Dow Jones Newswires; +49 (0)69 29725 108;
eyk.henning@dowjones.com
Watson (NYSE:WPI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Watson (NYSE:WPI)
Historical Stock Chart
From Mar 2023 to Mar 2024